It was revealed by Enable Injections that the Evendale medical device manufacturer has tapped into a contract of development with the pharmaceuticals and biotech company ‘Genentech’.
A disposable device is under development by rapidly-growing Enable called as the ‘enFuse’ which will enable the patients to insert a large dose of a prescription drug via the injection themselves just by touching a button. ‘En’ in enFuse stands for ‘enable’ whereas the fuse is short for infuse.
A wide range of products is marketed by Genentech, which is a San Francisco-based firm, for the treatment of serious, as well as, life-threatening medical conditions, inclusive of cancer. Genentech is a source of employment for over 13 thousand employees and is a subsidiary of the Roche Group of Switzerland. It also serves as the headquarters for operations of Roche pharmaceutical in the US.
The types of Genentech drugs were not revealed by the firms that might be dispensed by the enFuse device.
However, the collaboration is inclusive of the potential for various molecule development programs which will be incorporating long-term manufacturing, as well as, supply arrangements, Enable told via a statement.
The founder and Chief Executive Officer of Enable Injections, Mike Hooven, stated that with the enFuse paired for the delivery of certain subcutaneous therapeutics, it can now be potentially beneficial for patients all over the world.
The disposable enFuse device being invented by Enable Injections will be enabling the patients to inject prescription drugs their own selves by just the touch of a button.
The enFuse device could take place of the more expensive intravenous infusions which require the visit to any healthcare facility. On the abdomen, the Enable injector would be worn where it could be concealed by clothing. After the dispensing of medicine is dispensed, the needle retracts automatically, the device is peeled off by the patient and then is thrown away.